Locally instilled tumor necrosis factor-α antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs

Journal of Gene Medicine

Volumn 14, Issue 6, 2012, Pages 374-383

  Luo, Yi ^a   Pang, Zhonghua ^a   Zhu, Qian ^a   Cai, Xing ^a   Yin, Yuan ^a   Wang, Min ^a   Zhu, Jie ^a   Chen, Jiangning ^a   Zeng, Ke ^a   Zhang, Chenyu ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Allergic airway inflammation; Anti TNF therapeutics; Antisense oligonucleotide; Regulatory T cells; TH2 cell driven inflammation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD137 LIGAND; CYTOKINE; ISIS 25302; OVALBUMIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC AIRWAY INFLAMMATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; ASTHMA; ATTENUATION; CD4+ CD25+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; TH2 CELL; THYMUS;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; OVALBUMIN; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84862876757     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2631     Document Type: Article

References (41)

1. Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol 2003; 3: 405-412.
2. H2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
3. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8: 218-230.
4. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumour necrosis factor α in refractory asthma. N Engl J Med 2006; 354: 697-708.
5. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018.
6. Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligossa D, Stylianouc M, Levinea SJ. Effect of tumour necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005; 99: 1175-1182.
7. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomized, placebo controlled trial. Thorax 2008; 63: 584-591.
8. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumour necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174: 753-762.
9. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumour necrosis factor α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-558.
10. Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int 2011; 31: 327-337.
11. Matera MG, Calzetta L, Cazzola M. TNF-α inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 2010; 23: 121-128.
12. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114: 1425-1433.
13. Brightling C, Berry M, Amrani Y. Targeting TNF-α: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121: 5-10.
14. Popescu FD. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005; 9: 840-853.
15. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293.
16. Guimond A, Viau E, Aubé P, Renzi PM, Paquet L, Ferrari N. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 2008; 21: 845-854.
17. Zuo L, Huang Z, Dong L, et al. Targeting delivery of anti-TNF-α oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 2010; 59: 470-479.
18. Douglas SR. The role of the T cell in asthma. J Allergy Clin Immunol 2010; 126: 1081-1091.
19. Lukacs NW. Role of chemokines in the pathogenesis of asthma. Nat Rev Immunol 2001; 1: 108-116.
20. Koo GC, Shah K, Ding GJ, et al. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am J Respir Crit Care Med 2003; 167: 1400-1409.
21. Adachi T, Choudhury BK, Stafford S, Sur S, Alam R. The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000; 165: 2198-2204.
22. + T cell-dependent airway mucus production occurs in response to IL-5 expression in lung. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1066-L1074.
23. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 779-788.
24. Tournoy KG, Kips JC, Pauwels RA. Is Th1 the solution for Th2 in asthma? Clin Exp Allergy 2002; 32: 17-29.
25. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 77-79.
26. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103: 175-183.
27. Dahl ME, Dabbagh K, Liggitt D, Kim S, Lewis DB. Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells. Nat Immunol 2004; 5: 337-343.
28. Randolph DA, Stephens R, Carruthers CJ, Chaplin DD. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999; 104: 1021-1029.
29. Umetsu DT, DeKruyff RH. The regulation of allergy and asthma. Immunol Rev 2006; 212: 238-255.
30. Venuprasad K, Elly C, Gao M, et al. Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest 2006; 116: 1117-1126.
31. + regulatory T cells is interleukin 10 dependent. J Exp Med 2005; 202: 1539-1547.
32. Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille JJ. Curotto de Lafaille MA. Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 2005; 115: 1923-1933.
33. Goswami S, Angkasekwinai P, Shan M, et al. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol 2009; 10: 496-503.
34. Wu AJ, Hua H, Munson SH, McDevitt HO. Tumour necrosis factor-α regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002; 99: 12287-12292.
35. Deepe GS Jr, Gibbons RS. TNF-α antagonism generates a population of antigen-specific CD4+CD25+ T cells that inhibit protective immunity in murine histoplasmosis. J Immunol 2008; 180: 1088-1097.
36. Curiel TJ. Regulatory T-cell development: is Foxp3 the decider? Nat Med 2007; 13: 250-253.
37. Beier KC, Kallinich T, Hamelmann E. Master switches of T-cell activation and differentiation. Eur Respir J 2007; 29: 804-812.
38. Morris GP, Chen L, Kong YC. CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 2003; 226: 20-29.
39. Choi BK, Bae JS, Choi EM, et al. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 2004; 75: 785-791.
40. Zheng G, Wang B, Chen A. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 2428-34.
41. Seo SK, Park HY, Choi JH, et al. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol 2003; 171: 576-583.